However, the IFN-β treatment reverses the impaired AM function in response to the IL-10 at the late stage of sepsis and decreases the severity of sepsis-associated ALI/ARDS and the associated mortality (228). The gene discussed is IFNB1; the disease is acute respiratory distress syndrome.